Zomig-ZMT Orally Disintegrating Tablets Response Rates

Zomig is indicated for the acute treatment of migraine with or without aura in adults, where a clear diagnosis of migraine has been established. Zomig is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Zomig is not indicated for cluster headache.

See below for Complete Indication and Important Safety Information.

Zomig-ZMT delivers fast migraine pain relief—it starts working at 60 minutes for some and at 2 hours for many.1,2

Zomig-ZMT—Migraine Headache Response* Rate1,2

Dowson et al

For First Attack

zomig-zmt migraine response rates
  • At 1 hour, the response rate was significantly better than with placebo: 45% with Zomig-ZMT 2.5 mg vs. 19% with placebo, increasing to 63% at 2 hours vs. 22% with placebo (P<.0001 vs. placebo for both time points)1,2
  • In a separate multicenter, randomized, double-blind, placebo-controlled study, headache response rates with Zomig-ZMT 5 mg (n=329) were 16.5%, 41.1%, and 59.0% at 30 minutes, 1 hour, and 2 hours, respectively, vs. 12.5%, 22.9%, and 30.6% with placebo (n=341) (P=.048 at 30 minutes and P<.0001 at 1 hour and 2 hours vs. placebo). The primary end point was headache response rate at 30 minutes after the initial dose of the study drug, determined over 2 attacks3
  • In the only direct comparison of Zomig 2.5 mg and 5 mg, which used the conventional tablet formulation, there was little added benefit from the larger dose, but side effects were generally increased at 5 mg. Patients should, therefore, be started on 2.5 mg or lower. It is not recommended to break the orally disintegrating tablet. A dose lower than 2.5 mg can be achieved using the conventional tablet formulation by manually breaking the scored 2.5 mg tablet in half1
  • *Defined as a reduction in headache severity from moderate or severe pain to mild or no pain.
  • †From a single multicenter, randomized, double-blind, placebo-controlled study that included Zomig 2.5 mg (n=231) vs. placebo (n=239) for the acute treatment of moderate or severe migraines in adults.1,2

Zomig-ZMT—Pain-Free Response‡ Rate1,2

Dowson et al

For First Attack

zomig-zmt pain free response rates
  • Secondary end points evaluated in this study included pain-free response‡ rates at 1 hour, 2 hours, and 4 hours. Pain-free response rates with Zomig-ZMT 2.5 mg (n=231) were 8%, 27%, and 37% at 1 hour, 2 hours, and 4 hours, respectively, vs. 3%, 7%, and 11% with placebo (P=.0207 at 1 hour and P<.0001 at 2 hours and 4 hours vs. placebo). The primary end point in this study was headache response rate at 2 hours postdose1,2
  • In a separate multicenter, randomized, double-blind, placebo-controlled study, pain-free response‡ rates with Zomig-ZMT 5 mg (n=329) were 1.0%, 10.6%, and 31.1% at 30 minutes, 1 hour, and 2 hours, respectively, vs. 0.6%, 4.4%, and 11% with placebo (n=341) (P=NS at 30 minutes, P=.0002 at 1 hour, and P<.0001 at 2 hours vs. placebo). The primary end point in this study was headache response rate at 30 minutes after the initial dose of the study drug, determined over 2 attacks3
  • In the only direct comparison of Zomig 2.5 mg and 5 mg, which used the conventional tablet formulation, there was little added benefit from the larger dose, but side effects were generally increased at 5 mg. Patients should, therefore, be started on 2.5 mg or lower. It is not recommended to break the orally disintegrating tablet. A dose lower than 2.5 mg can be achieved using the conventional tablet formulation by manually breaking the scored 2.5 mg tablet in half1
  • ‡Pain-free response was defined as a reduction in headache pain from severe or moderate pain to no pain.
  • §From a multicenter, randomized, double-blind, placebo-controlled study of Zomig-ZMT 2.5 mg (n=231) vs. placebo (n=239) for the acute treatment of moderate or severe migraine in adults.1,2